Equities analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to announce $800,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $600,000.00. The business is expected to announce its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current financial year, with estimates ranging from $680,000.00 to $1.68 million. For the next fiscal year, analysts expect that the business will post sales of $19.57 million per share, with estimates ranging from $12.06 million to $28.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million.

A number of research firms have issued reports on ACRS. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a report on Tuesday, October 10th. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 4th. Finally, ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $39.20.

Aclaris Therapeutics (ACRS) traded up $0.44 during mid-day trading on Friday, reaching $24.63. 177,537 shares of the company’s stock were exchanged, compared to its average volume of 427,609. Aclaris Therapeutics has a one year low of $21.32 and a one year high of $33.25. The company has a market capitalization of $759.47, a PE ratio of -11.40 and a beta of 1.96.

Institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its position in shares of Aclaris Therapeutics by 40.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after buying an additional 17,804 shares during the last quarter. Cadence Capital Management LLC acquired a new position in shares of Aclaris Therapeutics during the third quarter valued at about $689,000. Boothbay Fund Management LLC raised its position in shares of Aclaris Therapeutics by 60.3% during the third quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock valued at $535,000 after buying an additional 7,791 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after buying an additional 697,104 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in shares of Aclaris Therapeutics by 620.6% during the third quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock valued at $6,247,000 after buying an additional 208,429 shares during the last quarter. 92.02% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/07/aclaris-therapeutics-inc-acrs-expected-to-announce-quarterly-sales-of-800000-00.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.